Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.55 |
| ▸ | PPARG | P37231 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465063 | 0.90 | TAAR1 (0.47) | PPARAPPARGCYP2D6CHRM2CHRM1 | |
| SCHEMBL4568868 | 0.85 | CYP2D6 (0.55) | PPARAPPARGCYP2D6KDM4EALDH1A1 | |
| SCHEMBL7775276 | 0.85 | CYP4F2 (0.51) | PPARAPPARGCYP2D6CHRM2CHRM1 | |
| SCHEMBL4568869 | 0.85 | CYP2D6 (0.57) | PPARAPPARGCYP2D6KDM4EALDH1A1 | |
| SCHEMBL14280090 | 0.85 | PPARA (0.68) | PPARAPPARGCYP2D6 | |
| SCHEMBL8986274 | 0.84 | PPARA (0.59) | PPARAPPARGCYP2D6CHRM2CHRM1 | |
| SCHEMBL4568871 | 0.83 | PPARA (0.61) | PPARAPPARGCYP2D6 | |
| SCHEMBL27655773 | 0.83 | TAAR1 (0.47) | CYP2D6CHRM2CHRM1CHRM3TAAR1 | |
| SCHEMBL27431797 | 0.83 | GABRA1 (0.55) | PPARAPPARGCHRM2CHRM1CHRM3 | |
| SCHEMBL145383 | 0.82 | CHRM2 (0.65) | CHRM2CHRM1CHRM3TAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999090-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI CO., LTD (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999090-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI CO., LTD (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999090-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI CO., LTD (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7928209-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7928209-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7928209-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7910712-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7910712-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7910712-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7897387-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7375204-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375204-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| CN-1873002-A | Fungal cell wall synthesis gene | EISAI CO LTD (JP) | 2006-12-06 | — | — | CN | disclosed |
| CN-1873003-A | Fungal cell wall synthesis gene | EISAI CO LTD (JP) | 2006-12-06 | — | — | CN | disclosed |
| US-20060234283-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| US-20060234349-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| CN-1249227-C | Fungal cell wall synthetic genes | EISAI CO LTD (JP) | 2006-04-05 | — | — | CN | disclosed |
| US-20040038239-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| CN-1449443-A | Fungal cell wall synthetic genes | EISAI CO LTD (JP) | 2003-10-15 | — | — | CN | disclosed |
| EP-1300464-A1 | FUNGAL CELL WALL SYNTHESIS GENE | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038239-A1 | Fungal cell wall synthesis gene | ERG28, GPI, DPM1 | PPARA 4804/4885PPARG 4723/4885CYP2D6 1894/4885 |
| US-20060234349-A1 | Fungal cell wall synthesis gene | ERG28, GPI, DPM1 | PPARA 4804/4885PPARG 4723/4885CYP2D6 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.